{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:15:04Z","timestamp":1788491704909,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"DOI":"10.1007\/s40119-026-00475-3","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:53:26Z","timestamp":1788490406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex Differences in a Contemporary, Real-World Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis"],"prefix":"10.1007","author":[{"given":"Marianna","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Generosa","family":"Crespo-Leiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian aus dem","family":"Siepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot K.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"8","key":"475_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7(8):709\u201316. https:\/\/doi.org\/10.1016\/j.jchf.2019.04.010.","journal-title":"JACC Heart Fail"},{"issue":"22","key":"475_CR2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"475_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","volume":"7","author":"C Rapezzi","year":"2010","unstructured":"Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398\u2013408. https:\/\/doi.org\/10.1038\/nrcardio.2010.67.","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"475_CR4","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286\u2013300. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.078915.","journal-title":"Circulation"},{"issue":"1","key":"475_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038169.","journal-title":"Circulation"},{"issue":"11","key":"475_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"issue":"3","key":"475_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","volume":"31","author":"P Garcia-Pavia","year":"2025","unstructured":"Garcia-Pavia P, Kristen AV, Drachman B, et al. Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). J Card Fail. 2025;31(3):525\u201333. https:\/\/doi.org\/10.1016\/j.cardfail.2024.06.003.","journal-title":"J Card Fail"},{"issue":"4","key":"475_CR8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40119-025-00421-9","volume":"14","author":"J Wixner","year":"2025","unstructured":"Wixner J, Dispenzieri A, Amass L, et al. Survival in a contemporary, real-world cohort of patients with mixed-phenotype transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from THAOS. Cardiol Ther. 2025;14(4):583\u201399. https:\/\/doi.org\/10.1007\/s40119-025-00421-9.","journal-title":"Cardiol Ther"},{"issue":"1","key":"475_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10741-020-10010-8","volume":"26","author":"M Bruno","year":"2021","unstructured":"Bruno M, Casta\u00f1o A, Burton A, Grodin JL. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. Heart Fail Rev. 2021;26(1):35\u201345. https:\/\/doi.org\/10.1007\/s10741-020-10010-8.","journal-title":"Heart Fail Rev"},{"issue":"12","key":"475_CR10","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1002\/ejhf.2674","volume":"24","author":"C Rapezzi","year":"2022","unstructured":"Rapezzi C, Emdin M, Aimo A. Unravelling the role of sex in the pathophysiology, phenotypic expression and diagnosis of cardiac amyloidosis. Eur J Heart Fail. 2022;24(12):2364\u20136. https:\/\/doi.org\/10.1002\/ejhf.2674.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"475_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/13506129.2025.2507921","volume":"32","author":"A Zaroui","year":"2025","unstructured":"Zaroui A, Lafont C, Kharoubi M, et al. Men and women differ with regard to the prevalence, phenotype, and prognosis of wild-type transthyretin amyloid cardiomyopathy. Amyloid. 2025;32(3):255\u201366. https:\/\/doi.org\/10.1080\/13506129.2025.2507921.","journal-title":"Amyloid"},{"issue":"3","key":"475_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40119-022-00265-7","volume":"11","author":"CM Campbell","year":"2022","unstructured":"Campbell CM, LoRusso S, Dispenzieri A, et al. Sex differences in wild-type transthyretin amyloidosis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Cardiol Ther. 2022;11(3):393\u2013405. https:\/\/doi.org\/10.1007\/s40119-022-00265-7.","journal-title":"Cardiol Ther"},{"issue":"8","key":"475_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101086","volume":"3","author":"N Mora-Ayestaran","year":"2024","unstructured":"Mora-Ayestaran N, Dispenzieri A, Kristen AV, et al. Age- and sex-related differences in patients with wild-type transthyretin amyloidosis: insights from THAOS. JACC Adv. 2024;3(8):101086. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101086.","journal-title":"JACC Adv"},{"issue":"10","key":"475_CR14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jchf.2021.05.005","volume":"9","author":"AG Caponetti","year":"2021","unstructured":"Caponetti AG, Rapezzi C, Gagliardi C, et al. Sex-related risk of cardiac involvement in hereditary transthyretin amyloidosis: insights from THAOS. JACC Heart Fail. 2021;9(10):736\u201346. https:\/\/doi.org\/10.1016\/j.jchf.2021.05.005.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"475_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1185\/03007995.2012.754349","volume":"29","author":"V Plante-Bordeneuve","year":"2013","unstructured":"Plante-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin. 2013;29(1):77\u201384. https:\/\/doi.org\/10.1185\/03007995.2012.754349.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"475_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15(1):e008193. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008193.","journal-title":"Circ Heart Fail"},{"issue":"10 Pt 2","key":"475_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102122","volume":"4","author":"MG Crespo-Leiro","year":"2025","unstructured":"Crespo-Leiro MG, Hanna M, Damy T, et al. Early access to tafamidis for patients with transthyretin amyloid cardiomyopathy. JACC Adv. 2025;4(10 Pt 2):102122. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102122.","journal-title":"JACC Adv"},{"issue":"12","key":"475_CR18","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1002\/ejhf.2646","volume":"24","author":"RK Patel","year":"2022","unstructured":"Patel RK, Ioannou A, Razvi Y, et al. Sex differences among patients with transthyretin amyloid cardiomyopathy\u2014from diagnosis to prognosis. Eur J Heart Fail. 2022;24(12):2355\u201363. https:\/\/doi.org\/10.1002\/ejhf.2646.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"475_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/gim.2016.200","volume":"19","author":"JN Buxbaum","year":"2017","unstructured":"Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017;19(7):733\u201342. https:\/\/doi.org\/10.1038\/gim.2016.200.","journal-title":"Genet Med"},{"issue":"7","key":"475_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1056\/NEJM199702133360703","volume":"336","author":"DR Jacobson","year":"1997","unstructured":"Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336(7):466\u201373. https:\/\/doi.org\/10.1056\/NEJM199702133360703.","journal-title":"N Engl J Med"},{"key":"475_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeaf175","author":"J Vogel","year":"2026","unstructured":"Vogel J, Jura S, Settelmeier S, et al. Sex-specific differences in cardiac transthyretin amyloidosis: addressing the diagnostic gap in women. Eur Heart J Open. 2026. https:\/\/doi.org\/10.1093\/ehjopen\/oeaf175.","journal-title":"Eur Heart J Open"},{"issue":"1","key":"475_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1542-474X.2009.00345.x","volume":"15","author":"AJ Moss","year":"2010","unstructured":"Moss AJ. Gender differences in ECG parameters and their clinical implications. Ann Noninvasive Electrocardiol. 2010;15(1):1\u20132. https:\/\/doi.org\/10.1111\/j.1542-474X.2009.00345.x.","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"4","key":"475_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006134","volume":"13","author":"LK Truby","year":"2020","unstructured":"Truby LK, O\u2019Connor C, Fiuzat M, et al. Sex differences in quality of life and clinical outcomes in patients with advanced heart failure: insights from the PAL-HF trial. Circ Heart Fail. 2020;13(4):e006134. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006134.","journal-title":"Circ Heart Fail"},{"key":"475_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092825","author":"A Garay","year":"2020","unstructured":"Garay A, Tapia J, Anguita M, et al. Gender differences in health-related quality of life in patients with systolic heart failure: results of the VIDA multicenter study. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9092825.","journal-title":"J Clin Med"},{"issue":"4","key":"475_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00392-014-0786-z","volume":"104","author":"J Franke","year":"2015","unstructured":"Franke J, Lindmark A, Hochadel M, et al. Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the heart failure survival score. Clin Res Cardiol. 2015;104(4):334\u201341. https:\/\/doi.org\/10.1007\/s00392-014-0786-z.","journal-title":"Clin Res Cardiol"},{"issue":"10","key":"475_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019712","volume":"10","author":"MA Daubert","year":"2021","unstructured":"Daubert MA, Yow E, Barnhart HX, et al. Differences in NT-proBNP response and prognosis in men and women with heart failure with reduced ejection fraction. J Am Heart Assoc. 2021;10(10):e019712. https:\/\/doi.org\/10.1161\/JAHA.120.019712.","journal-title":"J Am Heart Assoc"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00475-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00475-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00475-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:53:28Z","timestamp":1788490408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00475-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":26,"alternative-id":["475"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00475-3","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marianna Fontana: Consultancy and advisory board fees from Alexion, Alnylam, AstraZeneca, Attralus, BridgeBio, Caelum Biosciences, Cardior, Eidos, Intellia Therapeutics, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Lexeo Therapeutics, Novo Nordisk, Pfizer, and Prothena and has received research grants from Alnylam, AstraZeneca, BridgeBio, and Pfizer, and has received a salary from a British Heart Foundation Intermediate Fellowship. Alberto Aimo: nothing to disclose. Martha Grogan: Research funding: Alnylam, Eidos, Janssen, Pfizer, and Novo Nordisk; license\/patent pending from Anumana (algorithm to detect cardiac amyloidosis using AI ECG); advisory board: Alnylam, AstraZeneca, BridgeBio, Janssen, and Novo Nordisk. Maria Generosa Crespo-Leiro: Institutional grants from Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV) and Pfizer; honoraria for advisory board participation from Novo Nordisk; travel grants from Pfizer; and personal fees for scientific lectures from Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Novartis, and Vifor Pharma. Mathew S. Maurer: Grants and personal fees from Eidos, Ionis, Pfizer, and Prothena; grants from Alnylam; and personal fees from Akcea and GSK. Fabian aus dem Siepen: Speaker fees from Pfizer, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and Janssen, and consulting fees from Pfizer and Akcea Therapeutics. Mazen Hanna: Honoraria for advisory board participation from Akcea, Alexion Pharmaceuticals, Alnylam, BridgeBio, and Pfizer; and one-time speaker fees from Alnylam. Diego Delgado: Research grants and consultant for Pfizer, Alnylam and AstraZeneca. Martin Carlsson: Employee of and owns stock\/stock options in Pfizer. Thibaud Damy: Consulting fees from Alnylam, GlaxoSmithKline, Pfizer, and Prothena; honoraria from Alnylam, Pfizer, and Prothena; research grants from GlaxoSmithKline and Pfizer; and clinical trial support from Alnylam, Ionis, and Pfizer. Margot K. Davis: Honoraria from Alnylam Pharmaceuticals, AstraZeneca, Bayer, Novo Nordisk, and Pfizer; consulting fees from Alnylam Pharmaceuticals, Anthos, AstraZeneca, Bayer, BridgeBio Pharma Inc., Novo Nordisk, and Pfizer; research funding from Pfizer.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both studies were approved by the independent review board or ethics committee at each participating center and were conducted in accordance with the concepts laid out in the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. All patients provided written informed consent.","order":2,"name":"Ethics","label":"Ethics\/Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}